Oxford BioDynamics (GB:OBD) has released an update.
Oxford BioDynamics has published a study showcasing its EpiSwitch prognostic Covid Severity Test, which demonstrates a high predictive value for identifying severe COVID-19 outcomes. The test, based on a 6-marker model, accurately predicted high-risk cases and offers insights into Long COVID and Chronic Fatigue Syndrome. This development could bolster investor confidence in the company’s innovative 3D genomics platform and its potential applications in precision medicine.
For further insights into GB:OBD stock, check out TipRanks’ Stock Analysis page.
